Journal article icon

Journal article

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis

Abstract:

Objective: Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2 that is efficacious in patients with rheumatoid arthritis (RA). This study analyzed changes in lymphocyte cell subsets during baricitinib treatment and correlated such changes with clinical outcomes of baricitinib treatment.

Methods: An integrated analysis was conducted by pooling data from three completed Phase 3 trials comparing placebo and baricitinib treatment...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/art.40680

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Role:
Author
ORCID:
0000-0001-7766-6167
Expand authors...
Incyte Corporation More from this funder
Eli Lilly and Company More from this funder
Publisher:
John Wiley and Sons, Ltd. Publisher's website
Journal:
Arthritis and Rheumatology Journal website
Volume:
70
Issue:
12
Pages:
1923-1932
Publication date:
2018-07-29
Acceptance date:
2018-06-27
DOI:
EISSN:
2326-5205
ISSN:
2326-5191
Source identifiers:
860150
Pubs id:
pubs:860150
UUID:
uuid:ce0aca2b-d59a-4549-8a52-7f0315b79753
Local pid:
pubs:860150
Deposit date:
2018-07-02

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP